As more people turn to the obesity drug semaglutide (sold under the brand names Ozempic and Wegovy) to lose weight fast, the medical community is concerned that innovations for obesity—a chronic disease with serious health consequences—are being co-opted by the more sales-focused weight-loss market. In the first of a new series for STAT, Elaine Chen and Matthew Herper highlight the tension points and worrying intrusion of marketing and financial priorities in what should be the treatment of a medical condition. |